AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
Status:
Completed
Trial end date:
2009-05-27
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects
undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.